EQRx, Inc.
Index- P/E- EPS (ttm)-7.65 Insider Own16.37% Shs Outstand473.06M Perf Week-12.94%
Market Cap2.38B Forward P/E- EPS next Y-0.83 Insider Trans0.00% Shs Float407.89M Perf Month1.63%
Income- PEG- EPS next Q-0.21 Inst Own60.50% Short Float4.52% Perf Quarter21.17%
Sales- P/S- EPS this Y58.40% Inst Trans1.36% Short Ratio7.69 Perf Half Y52.76%
Book/sh3.12 P/B1.60 EPS next Y-43.10% ROA- Target Price6.80 Perf Year-49.70%
Cash/sh3.26 P/C1.53 EPS next 5Y- ROE- 52W Range2.63 - 9.99 Perf YTD-26.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.15% Beta-
Dividend %- Quick Ratio28.70 Sales past 5Y- Gross Margin- 52W Low89.35% ATR0.46
Employees242 Current Ratio28.70 Sales Q/Q- Oper. Margin- RSI (14)47.60 Volatility11.08% 8.86%
OptionableYes Debt/Eq0.00 EPS Q/Q52.10% Profit Margin- Rel Volume0.49 Prev Close4.82
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume2.40M Price4.98
Recom1.70 SMA20-4.10% SMA501.31% SMA200-11.70% Volume1,191,880 Change3.32%
Jun-13-22Initiated Goldman Buy $8
Apr-22-22Initiated Cowen Outperform
Mar-18-22Initiated Jefferies Buy $5.60
Aug-11-22 07:00AM  
Aug-07-22 04:10AM  
Jul-28-22 08:00AM  
Jul-03-22 08:22AM  
Jun-14-22 07:00AM  
May-31-22 08:00AM  
May-26-22 05:00PM  
May-13-22 07:00AM  
Apr-29-22 08:00AM  
Apr-27-22 10:30AM  
Mar-24-22 11:39AM  
Mar-23-22 07:00AM  
Mar-09-22 08:00AM  
Mar-02-22 08:00AM  
Jan-18-22 07:00PM  
Jan-10-22 07:30AM  
Jan-07-22 08:00AM  
Jan-03-22 08:00AM  
Dec-24-21 06:35AM  
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.